Antonino Bella1, Francesco Gesualdo2, Andrea Orsi3, Claudia Arcuri3, Maria Chironna4, Daniela Loconsole4, Christian Napoli5, Giovanni Battista Orsi6, Ilaria Manini7, Emanuele Montomoli7, Valeria Alfonsi1,5, Maria Rita Castrucci1, Caterina Rizzo2. 1. a Department of Infectious Diseases , National Institute of Health , Rome , Italy. 2. b Direction of Cinical Department , Bambino Gesù Children's Hospital , Rome , Italy. 3. c Department of Health Sciences , University of Genoa, IRCCS Ospedale Policlinico San Martino , Genoa , Italy. 4. d Department of Biomedical Science and Medical Oncology of the University of Bari , Bari , Italy. 5. e Department of Medical-Surgical Sciences and Translational Medicine , University of Rome "Sapienza", Sant'Andrea Hospital , Rome , Italy. 6. f Department of Public Health and Infectious Diseases , University of Rome "Sapienza" , Rome , Italy. 7. g Department of Molecular and Developmental Medicine , University of Siena , Siena , Italy.
Abstract
Background: Evidence on influenza vaccine effectiveness (VE) in preventing mortality and morbidity in the elderly is weak. Our aim was to measure the VE against severe outcomes in the elderly. Methods: We conducted a multicentre hospital-based test-negative design (TND) case-control study, during the 2017/18 season, in four Italian hospitals. The study population included individuals aged ≥65 years hospitalized with Severe Acute Respiratory Infections (SARI). Patients were classified as cases and controls based on the results of the PCR influenza testing. We estimated VE by virus subtypes and specific VE for the trivalent adjuvanted vaccine (TIVadj). Results: 502 patients with SARI were enrolled: 118 (23.5%) tested positive (cases) and 384 (76.5%) tested negative (controls) for influenza. The adjusted VE of 48.5% for all vaccines was comparable to the adjusted VE for the TIVadj vaccine (48.3%). Adjusted VE for the TIVadj vaccine was 67.5% for A(H1N1)pdm09 and 44.5% for B viruses. Conclusion: We show a moderate adjusted VE of the TIVadj against all viruses, a good adjusted VE against A(H1N1)pdm09 strains and a moderate adjusted VE against B strains, despite a mismatch between the B circulating lineage and the lineage included in the vaccine. This is likely due to the cross-protection among B strains induced by the TIVadj in elderly patients.
Background: Evidence on influenza vaccine effectiveness (VE) in preventing mortality and morbidity in the elderly is weak. Our aim was to measure the VE against severe outcomes in the elderly. Methods: We conducted a multicentre hospital-based test-negative design (TND) case-control study, during the 2017/18 season, in four Italian hospitals. The study population included individuals aged ≥65 years hospitalized with Severe Acute Respiratory Infections (SARI). Patients were classified as cases and controls based on the results of the PCR influenza testing. We estimated VE by virus subtypes and specific VE for the trivalent adjuvanted vaccine (TIVadj). Results: 502 patients with SARI were enrolled: 118 (23.5%) tested positive (cases) and 384 (76.5%) tested negative (controls) for influenza. The adjusted VE of 48.5% for all vaccines was comparable to the adjusted VE for the TIVadj vaccine (48.3%). Adjusted VE for the TIVadj vaccine was 67.5% for A(H1N1)pdm09 and 44.5% for B viruses. Conclusion: We show a moderate adjusted VE of the TIVadj against all viruses, a good adjusted VE against A(H1N1)pdm09 strains and a moderate adjusted VE against B strains, despite a mismatch between the B circulating lineage and the lineage included in the vaccine. This is likely due to the cross-protection among B strains induced by the TIVadj in elderly patients.
Authors: Ilaria Manini; Andrea Camarri; Serena Marchi; Claudia Maria Trombetta; Ilaria Vicenti; Filippo Dragoni; Giacomo Lazzeri; Giovanni Bova; Emanuele Montomoli; Pier Leopoldo Capecchi Journal: Int J Environ Res Public Health Date: 2021-04-07 Impact factor: 3.390
Authors: Mahrukh Imran; Joan Puig-Barbera; Justin R Ortiz; Lauren Fischer; Dan O'Brien; Machaon Bonafede; James A Mansi; Constantina Boikos Journal: Open Forum Infect Dis Date: 2022-04-02 Impact factor: 4.423
Authors: Carlo Capalbo; Enrico Bertamino; Alessandro Zerbetto; Iolanda Santino; Andrea Petrucca; Rita Mancini; Rita Bonfini; Valeria Alfonsi; Stefano Ferracuti; Paolo Marchetti; Maurizio Simmaco; Giovanni Battista Orsi; Christian Napoli Journal: Int J Environ Res Public Health Date: 2020-11-16 Impact factor: 3.390